Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Breast 1

Conditions

Breast Neoplasms 438Triple Negative Breast Neoplasms 50Neoplasm Metastasis 24Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 22Colorectal Neoplasms 18Carcinoma, Intraductal, Noninfiltrating 18Neoplasms 16Pancreatic Neoplasms 14Prostatic Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 12Colonic Neoplasms 11Breast Neoplasms, Male 10Urinary Bladder Neoplasms 8Small Cell Lung Carcinoma 8Melanoma 8Fatigue 8Breast Carcinoma In Situ 8Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lymphedema 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Cancer Female 6Testicular Neoplasms 5Pain 5Esophageal Neoplasms 5

Interventions

glembatumumab vedotin 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × Breast × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡